display
Hamburg (dpa) - The drug researcher Evotec implemented more than hoped last year despite the Corona crisis.
The revenues rose by 12 percent to almost 501 million euros, as the MDax group announced on Thursday in Hamburg.
However, among other things, higher costs for research and development and the start-up of a new production facility depressed the result.
Adjusted earnings before interest, taxes, depreciation and amortization (adjusted Ebitda) fell to 106.6 million euros, but was somewhat better than analysts expected, in line with the Group's targets.
A year earlier, Evotec had earned around 123 million euros, at that time the group had also received payments from the pharmaceutical company Sanofi for the acquired site in Toulouse, France.
The bottom line was that profits fell to 6.3 million euros, also due to the elimination of tax credits in Italy, after 37.2 million euros in the previous year.
In 2021, Evotec aims to increase sales to between EUR 550 million and EUR 570 million.
The adjusted Ebitda is expected at 105 to 120 million euros.
The group expects less severe negative effects from the pandemic than in 2020.
display
© dpa-infocom, dpa: 210325-99-962600 / 2